Search

Your search keyword '"Haramburu, Françoise"' showing total 416 results
Start Over Author "Haramburu, Françoise"
416 results on '"Haramburu, Françoise"'

3. Analgesic switching in chronic users of dextropropoxyphene in France.

Author

Daveluy, Amélie, Bryan, Michael Charles, Miremont‐Salamé, Ghada, Lassalle, Régis, Lacueille, Clémentine, Grelaud, Angela, Floccia, Marie, Haramburu, Françoise, Lapeyre‐Mestre, Maryse, Micallef, Joëlle, and Salvo, Francesco

Subjects
OPIOID analgesics, ANALGESICS, DATABASES, OPIOIDS, DRUG utilization, ACETAMINOPHEN, CROSS-sectional method
Abstract

Background: The combination dextropropoxyphene/paracetamol (DXP/P) was the most prescribed opioid analgesic until its withdrawal in 2011. Objectives: This study investigated dispensations of analgesics in chronic users of DXP/P during the 18 months following its withdrawal. Methods: A cross‐sectional study repeated yearly was conducted by using the French reimbursement database from 2006 to 2015. Chronic DXP/P users were defined as patients who received at least 40 boxes of DXP/P in the year prior to withdrawal. Data on analgesic dispensing were analyzed at DXP/P withdrawal (T0) and then every 6 months for 18 months. Results: A total of 63 671 subjects had a DXP/P reimbursement in the year prior to its discontinuation, of whom 7.1% were identified as chronic users (mean age: 71.5 years, women: 68.7%). Among the patients taking DXP/P alone at T0 (74.6%), one fourth switched to a peripheral analgesic, one fourth to a combination of peripheral analgesic/opioid, one fourth to another opioid, and the others mainly discontinued their treatment (14.1%) or died. During the following 12 months, most of the subjects taking only peripheral analgesics continued this treatment, while half of the subjects with a combination of opioid/peripheral analgesic or taking only an analgesic remained on this type of treatment. Conclusion: Eighteen months after DXP/P withdrawal, more than 10% of patients stopped taking an analgesic. Vigilance is required regarding any change in analgesics by regularly reassessing patients' pain and, in the case of opioid treatments, by monitoring the risk of use disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. La mise en place des cohortes en France : pourquoi, pour qui, comment et avec quels moyens ?

Author

Adjibi, Yolande, Augendre-Ferrante, Béatrice, Banzet, Marie-Noëlle, Becquemont, Laurent, Bloch, Juliette, Calles, Brigitte, Chene, Geneviève, Chapelon, Françoise Clavel, Couderc, Monique, De Sahb, Rima, Ducimetiere, Pierre, Golinelli, Danièle, Haramburu, Françoise, Joubert, Jean-Michel, Lebrun, Eléonore, Pigeon, Martine, Scheck-Bine, Florence, Schmidely, Nathalie, Solesse, Anne, Veron, Didier, Vuillaume, Dominique, Walckenaer, Guillaume, Goehrs, Jean-Marie, Borel, Thomas, and Costagliola, Dominique

Published
2012
Full Text
View/download PDF

34. Génériques et modalités de substituabilité : propositions de méthodes pour évaluer l’équivalence, la traçabilité et le relevé de Pharmacovigilance

Author

Bagheri, Haleh, Biraben, Arnaud, Fagot, Jean-Paul, Hamel, Jean-Dominique, Kreft-Jaïs, Carmen, Haramburu, Françoise, Laroche, Marie-Laure, Le Louet, Hervé, Martray, Claire, Mascaro, Jacques, Pisano, Christian, Rosilio, Myriam, Rouby, Franck, Saint-Pierre, Alain, Singlas, Éric, Lamarque, Véronique, Merle, Louis, and Demarez, Jean Paul

Published
2008
Full Text
View/download PDF

35. Generics and Substitution Modalities: Proposed Methods for the Evaluation of Equivalence, Traceability and Pharmacovigilance Reporting

Author

Bagheri, Haleh, Biraben, Arnaud, Fagot, Jean-Paul, Hamel, Jean-Dominique, Kreft-Jaïs, Carmen, Haramburu, Françoise, Laroche, Marie-Laure, Le Louet, Hervé, Martray, Claire, Mascaro, Jacques, Pisano, Christian, Rosilio, Myriam, Rouby, Franck, Saint-Pierre, Alain, Singlas, Éric, Lamarque, Véronique, Merle, Louis, and Demarez, Jean Paul

Published
2008
Full Text
View/download PDF

42. Adverse drug reactions induced by cotrimoxazole: Still a lot of preventable harm.

Author

Coppry, Maïder, Duret, Stéphanie, Berdaï, Driss, Miremont‐Salamé, Ghada, Fourrier‐Réglat, Annie, Haramburu, Françoise, Rogues, Anne‐Marie, and Noize, Pernelle

Subjects
DRUG side effects, CO-trimoxazole, INAPPROPRIATE prescribing (Medicine), BLOOD diseases, PRODUCT attributes
Abstract

Owing to a broad spectrum and low cost antimicrobial, cotrimoxazole is largely prescribed. However, its use is associated with various adverse drug reactions (ADRs) that warrant to ensure rational prescribing. This study aimed to describe spontaneous reports of cotrimoxazole ADRs and to evaluate the quality of prescription in patients who had ADRs. Suspected cotrimoxazole‐induced ADRs cases reported to the Bordeaux regional pharmacovigilance center (France) during a 5‐year period were described. Seriousness was assessed according to international criteria. Quality of prescription was assessed by compliance with the Summary of Product Characteristics (SPC) and relevance of cotrimoxazole indication. Then, an ADR was considered as preventable if the cotrimoxazole indication was not relevant, or potentially preventable if indication was relevant but the prescription was not compliant with the SPC. A total of 96 cases were analyzed: median age was 60.5 years (range: 4–94); 59.4% of patients were male. ADRs were mostly cutaneous disorders (n = 46) and hematological disorders (n = 25). A total of 60 serious ADRs occurred in 55 patients. Prescribers complied with all SPC recommendations in 21.9% of cases. Indication of cotrimoxazole was relevant or highly relevant in 41 cases. In 58% of cases, the occurrence of a cotrimoxazole‐induced ADR would have been preventable or potentially preventable. In a context of increasing interest for this antibiotic to treat infections due to resistant bacteria, physicians should be more aware of the potential consequences of inappropriate prescribing cotrimoxazole and reserve its use when there is no alternative and under suitable monitoring. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Anciens utilisateurs chroniques de dextropropoxyphène : évolution de leurs délivrances d’antalgiques après l’arrêt de sa commercialisation en France

Author

Daveluy, Amélie, primary, Bryan, Michael Charles, additional, Miremont-Salamé, Ghada, additional, Lassalle, Régis, additional, Lacueille, Clémentine, additional, Grelaud, Angela, additional, Haramburu, Françoise, additional, Lapeyre-Mestre, Maryse, additional, Micallef, Joëlle, additional, and Salvo, Francesco, additional

Published
2021
Full Text
View/download PDF

46. Pharmaceutical market of analgesic medicines in Romania

Author

CAZACU, I., Fourrier-Reglat, Annie, Haramburu, Françoise, MOGOȘAN, C., GHEORGHE-CETEAN, S., VOȘTINARU, O., LOGHIN, F., Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
PharmacoEpi-Drugs, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, health care economics and organizations
Abstract

The aim of the present study was to evaluate the pharmaceutical market of analgesic medicines in Romania during 2011 - 2015. A retrospective descriptive analysis was conducted on sales data provided by IQVIA (formerly IMS Health). Data corresponded to the volume of analgesic sales in hospital and retail pharmacies, split up in units and value (EUR), in prescription only (POM) and over-the-counter (OTC) medication and by region. Data was estimated to cover 95% of the Romanian market. From 2011 to 2015, the analgesic pharmaceutical market increased by 18.7% in value and by 6.1% in units. It was mainly assured by the retail distribution channel (95%), both for OTC and POM. The highest sales (6.3 units/capita, 12.3 EUR/capita) were found for the capital, Bucharest, while the lowest for counties of the North-East region of Romania (3.5 units/capita, 6.0 EUR/capita). In the context of an increasing analgesic market, programs that promote rational use of these medicines should be a priority at present for the Romanian healthcare system.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results